CRESCENT BIOPHARMA, INC.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- CBIOCrescent Biopharma, Inc.0Calm
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Signing up patientsPhase 1/2219 patientsMain results: Oct 2028 - CBIOCrescent Biopharma, Inc.0Calm
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Signing up patientsPhase 1/2540 patientsMain results: Feb 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
16 sales (0 not pre-planned) · 1 purchase
- Brumm Joshua TChief Executive Officer · Sep 18, 2026Sold 7,837 sharesabout $131 thousand · pre-planned
- McNeill JonathanPresident and COO · Sep 18, 2026Sold 3,839 sharesabout $64 thousand · pre-planned
- Lynch RyanSee Remarks · Sep 16, 2026Sold 240 sharesabout $4 thousand · pre-planned
- Pinkas JanChief Scientific Officer · Sep 16, 2026Sold 658 sharesabout $12 thousand · pre-planned
- Im Ellie EunkyungChief Medical Officer · Sep 16, 2026Sold 623 sharesabout $11 thousand · pre-planned
- Scalzo Richard WilliamChief Financial Officer · Sep 16, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.